ALTAO
Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquart… Read more
ALTAO (ALTAO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 1.330x
Based on the latest financial reports, ALTAO (ALTAO) has a cash flow conversion efficiency ratio of 1.330x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€552.00K) by net assets (€415.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ALTAO - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how ALTAO's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ALTAO Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALTAO ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NRB Industrial Bearings Limited
NSE:NIBL
|
-0.018x |
|
Wawel S.A.
F:0K6
|
N/A |
|
Drago entertainment S.A.
WAR:DGE
|
-0.041x |
|
Stern Groep N.V.
AS:PBH
|
0.866x |
|
OZZ Resources Ltd
AU:OZZ
|
0.105x |
|
Nuinsco Resources Limited
PINK:NWIFF
|
0.024x |
|
SEATech Ventures Corp
PINK:SEAV
|
-0.092x |
|
Scisparc Ltd
NASDAQ:SPRC
|
22.975x |
Annual Cash Flow Conversion Efficiency for ALTAO (2009–2024)
The table below shows the annual cash flow conversion efficiency of ALTAO from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €791.00K | €510.00K | 0.645x | -11.74% |
| 2023-12-31 | €-4.69 Million | €-3.42 Million | 0.730x | +188.07% |
| 2017-12-31 | €9.16 Million | €-7.60 Million | -0.829x | -252.89% |
| 2016-12-31 | €10.88 Million | €-2.56 Million | -0.235x | +28.45% |
| 2015-12-31 | €15.98 Million | €-5.25 Million | -0.328x | -5.07% |
| 2014-12-31 | €11.01 Million | €-3.44 Million | -0.313x | +72.04% |
| 2013-12-31 | €2.45 Million | €-2.74 Million | -1.118x | +40.46% |
| 2012-12-31 | €1.38 Million | €-2.60 Million | -1.878x | -163.47% |
| 2011-12-31 | €-915.00K | €-2.71 Million | 2.958x | -74.05% |
| 2010-12-31 | €-316.00K | €-3.60 Million | 11.399x | +2596.64% |
| 2009-12-31 | €2.66 Million | €-1.21 Million | -0.457x | -- |